Evidence map›Paper›PMID 35563166›Full record

ArticleInternational journal of molecular sciences2022

Tetraspanin CD9 Expression Predicts Sentinel Node Status in Patients with Cutaneous Melanoma.

Guendalina Lucarini, Elisa Molinelli, Caterina Licini, Giulio Rizzetto, Giulia Radi, Gaia Goteri, Monica Mattioli-Belmonte, Annamaria Offidani, Oriana Simonetti

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Efficacy of Pembrolizumab in Advanced Melanoma: A Narrative Review.International journal of molecular sciences · 2023
    Review
  5. Review
  6. Tissue Biomarkers Predicting Lymph Node Status in Cutaneous Melanoma.International journal of molecular sciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Guendalina LucariniDipartimento di Scienze Cliniche e Molecolari-Istologia, Università Politecnica delle Marche, 60126 Ancona, Italy.ORCID 0000-0003-3218-5620
Elisa MolinelliClinica Dermatologica, Dipartimento di Scienze Cliniche e Molecolari, Università Politecnica delle Marche, 60126 Ancona, Italy.
Caterina LiciniDipartimento di Scienze Cliniche e Molecolari-Istologia, Università Politecnica delle Marche, 60126 Ancona, Italy.ORCID 0000-0002-0018-8096
Giulio RizzettoClinica Dermatologica, Dipartimento di Scienze Cliniche e Molecolari, Università Politecnica delle Marche, 60126 Ancona, Italy.
Giulia RadiClinica Dermatologica, Dipartimento di Scienze Cliniche e Molecolari, Università Politecnica delle Marche, 60126 Ancona, Italy.
Gaia GoteriAnatomia Patologica, Dipartimento di Scienze Biomediche e Sanità Pubblica, Ospedali Riuniti, Università Politecnica delle Marche, 60126 Ancona, Italy.
Monica Mattioli-BelmonteDipartimento di Scienze Cliniche e Molecolari-Istologia, Università Politecnica delle Marche, 60126 Ancona, Italy.ORCID 0000-0002-2087-2776
Annamaria OffidaniClinica Dermatologica, Dipartimento di Scienze Cliniche e Molecolari, Università Politecnica delle Marche, 60126 Ancona, Italy.
Oriana SimonettiClinica Dermatologica, Dipartimento di Scienze Cliniche e Molecolari, Università Politecnica delle Marche, 60126 Ancona, Italy.
Marche Polytechnic University · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The tetraspanin CD9 is considered a metastasis suppressor in many cancers, however its role is highly debated. Currently, little is known about CD9 prognostic value in cutaneous melanoma. Our aim was to analyse CD9 expression in melanocytic nevi and primary cutaneous melanomas through immunohistochemistry and immunofluorescence approaches to determine its correlation with invasiveness and metastatic potential. CD9 displayed homogeneous staining in all melanocytic nevi. In contrast, it showed a complete loss of reactivity in all thin melanomas. Interestingly, CD9 was re-expressed in 46% of intermediate and thick melanomas in small tumor clusters predominantly located at sites of invasion near or inside the blood or lymphatic vessels. The most notable finding is that all CD9 stained melanomas presented sentinel node positivity. Additionally, a direct association between CD9 expression and presence of distant metastasis was reported. Finally, we confirm that CD9 expression is consistent with an early protective role against tumorigenesis, however, our data endorse in melanoma a specific function of CD9 in vascular dissemination during late tumor progression. The presence of CD9 hotspots could be essential for melanoma cell invasion in lymphatic and endothelial vessels. CD9 could be a valid prognostic factor for lymph node metastasis risk.

Indexed as

MelanomaNevus, PigmentedSkin NeoplasmsCutaneous Malignant MelanomaHumansSentinel Lymph Node BiopsyTetraspanin 29TetraspaninsCD9 protein, humanTetraspanin 29Tetraspaninscutaneous melanomalymph node metastasismelanocytic neviprognostic markertetraspanin CD9transendothelial invasion

Identifiers

PMID35563166
PMCPMC9103426
OpenAlexW4224921533

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.